Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions

NCT05417893 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Operational and feasibility constraints due to regulatory requirements

Conditions

Coronary Artery Disease

Interventions

DEVICE: MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)

Sponsor

Meril Life Sciences Pvt. Ltd.